Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 236Carcinoma, Non-Small-Cell Lung 78Carcinoma, Renal Cell 61Neoplasm Metastasis 52Neoplasms 47Prostatic Neoplasms 34Uveal Melanoma 29Lung Neoplasms 28Pancreatic Neoplasms 27Carcinoma, Hepatocellular 25Brain Neoplasms 23Sarcoma 22Colorectal Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Skin Neoplasms 17Kidney Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Mesothelioma 13Uterine Cervical Neoplasms 12Recurrence 12Glioblastoma 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Scleroderma, Systemic × Ipilimumab × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡